5-S-cysteinyldopamine neurotoxicity: Influence on the expression of α-synuclein and ERp57 in cellular and animal models of Parkinson's disease

J Neurosci Res. 2014 Mar;92(3):347-58. doi: 10.1002/jnr.23318. Epub 2013 Nov 22.

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder whose etiology is still unclear in spite of extensive investigations. It has been hypothesized that 5-S-cysteinyldopamine (CysDA), a catechol-thioether metabolite of dopamine (DA), could be an endogenous parkinsonian neurotoxin. To gain further insight into its role in the neurodegenerative process, both CD1 mice and SH-SY5Y neuroblastoma cells were treated with CysDA, and the data were compared with those obtained by the use of 6-hydroxydopamine, a well-known parkinsonian mimetic. Intrastriatal injection of CysDA in CD1 mice caused a long-lasting depletion of DA, providing evidence of in vivo neurotoxicity of CysDA. Both in mice and in SH-SY5Y cells, CysDA treatment induced extensive oxidative stress, as evidenced by protein carbonylation and glutathione depletion, and affected the expression of two proteins, α-synuclein (α-Syn) and ERp57, whose levels are modulated by oxidative insult. Real-time PCR experiments support these findings, indicating an upregulation of both ERp57 and α-Syn expression. α-Syn aggregation was also found to be modulated by CysDA treatment. The present work provides a solid background sustaining the hypothesis that CysDA is involved in parkinsonian neurodegeneration by inducing extensive oxidative stress and protein aggregation.

Keywords: 5-S-cysteinyldopamine; 6-hydroxydopamine; ERp57; Parkinson's disease; α-synuclein.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biogenic Monoamines / metabolism
  • Brain / drug effects
  • Brain / metabolism*
  • Cell Line, Tumor
  • Disease Models, Animal
  • Dopamine / analogs & derivatives*
  • Dopamine / toxicity
  • Dopamine Agents / toxicity*
  • Dose-Response Relationship, Drug
  • Glutathione / metabolism
  • Glutathione Disulfide / metabolism
  • Humans
  • Male
  • Mice
  • Neuroblastoma / pathology
  • Oxidative Stress / drug effects
  • Oxidopamine / toxicity
  • Parkinson Disease / etiology*
  • Protein Carbonylation / drug effects
  • Protein Disulfide-Isomerases / genetics
  • Protein Disulfide-Isomerases / metabolism*
  • alpha-Synuclein / genetics
  • alpha-Synuclein / metabolism*

Substances

  • Biogenic Monoamines
  • Dopamine Agents
  • alpha-Synuclein
  • Oxidopamine
  • 5-S-cysteinyldopamine
  • Pdia3 protein, mouse
  • Protein Disulfide-Isomerases
  • Glutathione
  • Glutathione Disulfide
  • Dopamine